» Articles » PMID: 26009596

Familial Hypercholesterolaemia in Children and Adolescents: Gaining Decades of Life by Optimizing Detection and Treatment

Abstract

Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary heart disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and treated early in childhood, individuals with FH can have normal life expectancy. This consensus paper aims to improve awareness of the need for early detection and management of FH children. Familial hypercholesterolaemia is diagnosed either on phenotypic criteria, i.e. an elevated low-density lipoprotein cholesterol (LDL-C) level plus a family history of elevated LDL-C, premature coronary artery disease and/or genetic diagnosis, or positive genetic testing. Childhood is the optimal period for discrimination between FH and non-FH using LDL-C screening. An LDL-C ≥5 mmol/L (190 mg/dL), or an LDL-C ≥4 mmol/L (160 mg/dL) with family history of premature CHD and/or high baseline cholesterol in one parent, make the phenotypic diagnosis. If a parent has a genetic defect, the LDL-C cut-off for the child is ≥3.5 mmol/L (130 mg/dL). We recommend cascade screening of families using a combined phenotypic and genotypic strategy. In children, testing is recommended from age 5 years, or earlier if homozygous FH is suspected. A healthy lifestyle and statin treatment (from age 8 to 10 years) are the cornerstones of management of heterozygous FH. Target LDL-C is <3.5 mmol/L (130 mg/dL) if >10 years, or ideally 50% reduction from baseline if 8-10 years, especially with very high LDL-C, elevated lipoprotein(a), a family history of premature CHD or other cardiovascular risk factors, balanced against the long-term risk of treatment side effects. Identifying FH early and optimally lowering LDL-C over the lifespan reduces cumulative LDL-C burden and offers health and socioeconomic benefits. To drive policy change for timely detection and management, we call for further studies in the young. Increased awareness, early identification, and optimal treatment from childhood are critical to adding decades of healthy life for children and adolescents with FH.

Citing Articles

[Role of genetics in precision medicine of coronary artery disease].

Sanin V, Schmieder R, Koenig W, Li L, Schunkert H, Chen Z Herz. 2025; .

PMID: 40019575 DOI: 10.1007/s00059-025-05297-y.


Modelling a two-stage adult population screen for autosomal dominant familial hypercholesterolaemia: cross-sectional analysis within the UK Biobank.

Gratton J, Humphries S, Schmidt A, Patel R, Sofat R, Finan C BMJ Public Health. 2025; 1(1):e000021.

PMID: 40017868 PMC: 11812690. DOI: 10.1136/bmjph-2023-000021.


Exploring LDLR-APOB Interactions in Familial Hypercholesterolemia in the Vietnamese Population: A Protein-Protein Docking Approach.

Kim N, Do D, Nguyen M, Le H, Le T, Truong T Bioinform Biol Insights. 2024; 18:11779322241301267.

PMID: 39619738 PMC: 11605763. DOI: 10.1177/11779322241301267.


Targeted NGS Revealed Pathogenic Mutation in a 13-Year-Old Patient with Homozygous Familial Hypercholesterolemia: A Case Report.

Chamoieva A, Mirmanova Z, Zhalbinova M, Rakhimova S, Daniyarov A, Kairov U Int J Mol Sci. 2024; 25(22).

PMID: 39595952 PMC: 11593385. DOI: 10.3390/ijms252211882.


Association of magnesium intake with predicted atherosclerotic lesions and cardiovascular risk in young adults based on PDAY score: a cross-sectional study.

Song Q, Song L, Liu H, Tan H, Yang B, Fan C BMC Public Health. 2024; 24(1):3232.

PMID: 39567969 PMC: 11580479. DOI: 10.1186/s12889-024-20785-2.


References
1.
Kusters D, De Beaufort C, Widhalm K, Guardamagna O, Bratina N, Ose L . Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child. 2011; 97(3):272-6. DOI: 10.1136/archdischild-2011-300081. View

2.
de Jongh S, Lilien M, Roodt J, Stroes E, Bakker H, Kastelein J . Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002; 40(12):2117-21. DOI: 10.1016/s0735-1097(02)02593-7. View

3.
Rader D, Cohen J, Hobbs H . Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003; 111(12):1795-803. PMC: 161432. DOI: 10.1172/JCI18925. View

4.
McGill Jr H, McMahan C, Gidding S . Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation. 2008; 117(9):1216-27. DOI: 10.1161/CIRCULATIONAHA.107.717033. View

5.
Usifo E, Leigh S, Whittall R, Lench N, Taylor A, Yeats C . Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet. 2012; 76(5):387-401. DOI: 10.1111/j.1469-1809.2012.00724.x. View